| [1] |
Li M, Zhang SW, Ma JH, et al. A comparative study on incidence trends of prostate cancer in part of cities and counties in China[J]. Zhonghua Mi Niao Wai Ke Za Zhi,2009,30(6):368-70. [李鸣，张 思维，马建辉，等. 中国部分市县前列腺癌发病趋势比较研究 [J] 中华泌尿外科杂志, 2009,30(6):368-70.]
|
| [2] |
Ye DW, Li CL.Epidemiological trends of prostate cancer: retrospect and prospect[J]. Zhongguo Ai Zheng Za Zhi,2007,17(3):177-80.[叶 定伟,李长岭.前列腺癌发病趋势的回顾和展望[J]. 中国癌症杂 志,2007,17(3):177-80.]
|
| [3] |
Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates[J]. Eur Urol,2012,61(6):1079-92.
|
| [4] |
Ma CG, Ye DW, Li CL, et al. Epidemiology of prostate cancer from three centers and analysis of the first-fine hormonal therapy for the advanced disease[J]. Zhonghua Wai Ke Za Zhi,2008,46(12):921-5. [马春光，叶定伟，李长岭，等. 列腺癌 的流行病学特征及晚期一线内分泌治疗分析[J]. 中华外科杂 志,2008,46(12):921-5.]
|
| [5] |
Wang Y, Guo J, Xu L, et al. Should bone scan be performed in Chinese prostate cancer patients at the time of diagnosis?[J]. Urol Int,2013,91(2):160-4.
|
| [6] |
Groot MT, Boeken Kruger CG, Pelger RC, et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands[J]. Eur Urol,2003,43(3):226-32.
|
| [7] |
Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma[J]. Cancer,2000,88(12 Suppl):2989-94.
|
| [8] |
Rigaud J, Tiguert R, Le Normand L, et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy[J]. J Urol,2002,168(4 Pt 1) :1423-6.
|
| [9] |
Hsieh YY, Tsai HD, Chang FC. Routine blastocyst culture and transfer: 201 patients’ experience[J]. J Assist Reprod Genet,2000,17(8):405-8.
|
| [10] |
Na YQ. Guideline to diagnosis and treatment of urological diseases China[Z]. Beijing: People's Health Publishing House, 2011. [那彦 群．中国泌尿外科疾病诊断治疗指南[Z]．北京：人民卫生出 版社，2011.]
|
| [11] |
Lamb DS, Slaney D, Smart R, et al. Prostate cancer: the new evidence base for diagnosis and treatment[J]. Pathology,2007,39( 6) :537-44.
|
| [12] |
Wang Z,Zhou LQ,Gao JP,et al. Combination of prostate specifi c antigen and pathological stage regarding to gleason score to predict bone metastasis of newly diagnosed prostate cancer[J]. Biao Ji Mian Yi Fen Xi Yu Lin Chuang,2004,11(4):219-21.[王振, 周立权,高江平,等.血清PSA结合病理分级预测前列腺癌骨转移 [J] 标记免疫分析与临床,2004,11(4):219-21.]
|
| [13] |
Geng DZ. Chinese Geriatrics[M]. Beijing: People’s Health Publishing House, 2002:798.[耿德章. 中国老年医学[M]. 北京： 人民卫生出版社,2002:798.]
|
| [14] |
Chybowski FM, Keller JJ, Bergstralh EJ, et al. Predicting radionuclide bone scan fi ndings in patients with newly diagnosed, untreated prostate cancer: prostate specifi c antigen is superior to all other clinical parameters[J]. J Urol,1991,145(2):313-8.
|
| [15] |
Wolff JM, Zimny M, Borchers H, et al. Is prostate-specifi c antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?[J]. Eur Urol,1998,33(4):376-81.
|
| [16] |
Bruwer G, Heyns CF, Allen FJ. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate[J]. Eur Urol,1999,35(3):223-7.
|
| [17] |
Briganti A, Passoni N, Ferrari M, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratifi cation tool[J]. Eur Urol,2010,57(4):551-8.
|
| [18] |
Tanaka N, Fujimoto K, Shinkai T, et al. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of ≤20 ng/ml and Gleason score of ≤6 at the initial stage of diagnosis[J]. Jpn J Clin Oncol,2011,41(10):1209-13.
|
| [19] |
McArthur C, McLaughlin G, Meddings RN. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients[J]. Br J Radiol,2012,85(1012):390-4.
|
| [20] |
Birtle AJ, Freeman A, Masters JR, et al. Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specifi c antigen (PSA) levels < 10 ng/mL: the “PSA negative” patients[J]. Cancer,2003,98(11):2362-7.
|
| [21] |
Wang KL, Song LP. The diagnostic value of combining whole body bone images with serum PSA, fPSA and fPSA/PSA ratio in the diagnosis of bone metastasis in patients with prostate cancer[J]. Zhongguo Lin Chuang Yi Xue Ying Xiang Za Zhi,2012,23(9):672-4. [王开乐，宋丽萍. 全身骨显像联合血清 PSA、fPSA及fPSA/PSA比值对前列腺癌骨转移的诊断价值 [J] 中国临床医学影像杂志,2012,23(9):672-4.]
|
| [22] |
Tan WQ, Yang SJ. Analysis of relationship between serum PSA, fPSA levels and bone metastasis in prostatic cancer[J]. Fang She Mian Yi Xue Za Zhi,2007,20(2):160-2. [谭维琴，杨士军. 血清 PSA、fPSA浓度与前列腺癌骨转移的关系分析[J]. 放射免疫学 杂志,2007,20(2):160-2.]
|
| [23] |
Yang GF, Zuo SY, Wang GM, et al. Research of whole bone scanning in the diagnosis of metastatic diseases in prostate cancer, and its correlation with pathological grade and PSA[J]. Zhongguo Lin Chuang Yi Xue Ying Xiang Za Zhi, 2010,21(1):72-3. [杨 桂凤，左书耀，王国明，等. 骨显像诊断前列腺癌骨转 移与病理分级及PSA的关系探讨[J]. 中国临床医学影像杂 志,2010,21(1):72-3.]
|
| [24] |
Lorente JA, Valenzuela H, Morote J, et al. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specifi c antigen in the staging of newly diagnosed prostate cancer patients[J]. Eur J Nucl Med,1999,26(6):625-32.
|
| [25] |
Wymenga LF, Boomsma JH, Groenier K, et al. Routine bone scans in patients with prostate cancer related to serum prostate-specifi c antigen and alkaline phosphatase[J]. BJU Int,2001,88(3):226-30.
|
| [26] |
Zhang J, Liu ZL, Cui XJ, et al. The application of radionuclide bone scintigraphy,serum PSA and ALP measurement in diagnosis of bone metastasis in prostate cancer patients[J]. Suzhou Da Xue Xue Bao(Yi Xue Ban),2007,27(3):407-10. [张俊，刘 增礼，崔学军，等. 核素骨显像和血清PSA、ALP检测在 前列腺癌骨转移诊断中的价值[ J ] . 苏州大学学报（医学 版） ,2007,27(3):407-10.]
|
| [27] |
Li ZX. The clinical importance on detecting the BALP in prostatic carcinoma complicating osseous metastasis patients[J]. Zhongguo Shi Yan Zhen Duan Xue,2006,10(9):1074-6.[ 李振 雪. BALP在前列腺癌骨转移中的检测意义[J]. 中国实验诊断 学,2006,10(9):1074-6.]
|
| [28] |
Zhang XL,Zhang JS,Zhang JK, et al. The diagnostic value on detecting the BALP and f-PSA/t-PSA in patients with bone metastasis of prostatic cancer[J]. Zhongguo Shi Yan Zhen Duan Xue,2009,13(10):1381-3.[ 张晓丽，张吉生，张敬凯，等. BALP与f-PSA/t-PSA联合检测对前列腺癌骨转移诊断价值的 研究[J] 中国实验诊断学,2009,13(10):1381-3.]
|
| [29] |
Salminen E, Ala-Houhala M, Korpela J, et al. Serum tartrateresistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer[J]. Acta Oncol,2005,44(7):742-7.
|
| [30] |
Luo HL, Chen QC. Signifi cance of prostate specifi c antigen and markers of bone formation or resorption in diagnosis of bone metastasis of prostate cancer[J]. Zhonghua Lao Nian Yi Xue Za Zhi,2012,31(5):421-4.[ 楼慧玲，陈巧聪. 前列腺特异性抗原及 骨标志物检测对前列腺癌骨转移患者诊断的意义[J]. 中华老年 医学杂志,2012,31(5):421-4.]
|
| [31] |
Ozu C, Nakashima J, Horiguchi Y, et al. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specifi c antigen in patients with prostate cancer[J]. Int J Urol,2008,15(5):419-22.
|
| [32] |
Korpela J, Tiitinen SL, Hiekkanen H, et al. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer[J]. Anticancer Res,2006,26(4B):3127-32.
|
| [33] |
Kamiya N, Suzuki H, Yano M, et al. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis[J]. Urology,2010,75(6):1446-51.
|
| [34] |
Chen HX, Li HZ, Li HJ, et al. Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer[J]. Zhonghua Wai Ke Za Zhi,2007,45(6):412-4.[ 陈海昕，李汉忠，李宏军，等. 血清骨保护素诊断前列腺癌骨转移的初步研究[J]. 中华外科杂 志,2007,45(6):412-4.]
|
| [35] |
Wang YP,Huang X, Lu ZX. Significance of the β-CTX and P1NP combined detection in the diagnose of osseous metastasis of prostatic carcinoma[J]. Fang She Mian Yi Xue Za Zhi,2011,24(4):435-7.[ 王亚萍，黄璇，卢志贤. 血清β-CTX和 Total-P1NP联检在前列腺癌骨转移监测中的价值[J]. 放射免疫 学杂志,2011,24(4):435-7.]
|
| [36] |
Wang LJ, Fu HP. The clinical application of serum β-Crosslaps determination[J]. Jian Yan Yi Xue,2007,22(6):633-5.[ 王立军， 傅海平. 血清β-胶原特殊序列的测定及初步临床应用[J]. 检验 医学,2007,22(6):633-5].
|
| [37] |
Jin W, Wu B, Zhang H. Clinical significance of TGF-β1 levels change in prostate cancer patients[J]. Shandong Yi Yao,2011,51(42):63-4.[ 金玮，吴斌，张辉. 前列腺癌患者血浆 TGF-β1水平变化及临床意义[J]. 山东医药,2011,51(42):63-4.]
|
| [38] |
Liu HY,Mi ZG, Han XB, et al. Identifi cation of serum protein of prostate cancer with osseous metastasis[J]. Zhong Liu Yan Jiu Yu Lin Chuang,2011,23(3):197-200. [ 刘洪宇，米振国，韩雪冰， 等. 前列腺癌骨转移患者血清差异性相关蛋白质的筛选[J]. 肿 瘤研究与临床,2011,23(3):197-200.]
|
下载:
